Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Polycystic Kidney Disease | Treatment Algorithms: Claims Data Analysis | US | 2024
Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD), is a genetic disorder in which fluid-filled cysts progressively develop in the kidney…
Hemophilia B – Unmet Need – Unmet Need – Severe Noninhibitor Hemophilia B (US/EU)
Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX (FIX). Individuals with this condition experience prolonged bleeding. Prescribing options include factor balancing…
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in Breast Cancer, Ovarian Cancer, and Prostate Cancer (US)
Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…
Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2024
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Children with UC have a more-complicated disease course compared with adult patients…
Psoriasis | Treatment Algorithms: Claims Data Analysis | Pediatric Psoriasis | US | 2024
Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta, AstraZeneca’s Saphnelo and…
